Search
Showing results for "1"
Perth Children’s Hospital will be one of the first hospitals in Australia to deliver critical diabetes training to teachers and school staff as part of a new national Diabetes in Schools program.
Type 1 diabetes patients require about 50 per cent more insulin with a high protein meal then with a low protein meal to maintain a stable blood glucose level, according to new research from the Children’s Diabetes Centre at The Kids Research Institute Australia.
When Josh Wulf’s son was diagnosed with Type 1 Diabetes, little did he know that one day he would be helping other T1D families manage the condition.
The ENDIA study — Australia’s largest study into the causes of Type 1 Diabetes— reached a significant milestone when it recruited its 700th patient in Perth.
Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) and generalized arterial calcification of infancy (GACI) occur secondary to biallelic ectonucleotide pyrophosphate/phosphodiesterase 1 (ENPP1) loss-of-function pathogenic variants. GACI is a life-threatening condition, often presenting in the neonatal period with heart failure and hypertension, caused by calcification of the media in large- and medium-sized arteries.
The National Institute for Clinical Excellence updated guidance for continuous glucose monitoring (CGM) in 2022, recommending that CGM be available to all people living with type 1 diabetes. Manufacturers can trade in the UK with Conformité Européenne (CE) marking without an initial national assessment. The regulatory process for CGM CE marking, in contrast to the Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA) process, is described.
Find newsletters, guidelines, publications and videos in the one spot.
School is back for a new year, and with that comes the daily lunchbox preparation.
Did you know that regular exercise can literally add years to the lives of children living with Type 1 Diabetes?
Hybrid closed-loop (HCL) therapy is an efficacious management strategy for young people with type 1 diabetes. However, high costs prevent equitable access. We thus sought to evaluate the cost-effectiveness of HCL therapy compared with current care among young people with type 1 diabetes in Australia.